A Phase 1 Dose Escalation Safety Study Combining the ATR Inhibitor M6620 With Chemoradiotherapy in Oesophageal Cancer & Other Solid Cancers Using Time to Event Continual Reassessment Method
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Berzosertib (Primary) ; Capecitabine (Primary) ; Cisplatin (Primary)
- Indications Adenocarcinoma; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CHARIOT
- 27 Feb 2019 Status changed from not yet recruiting to recruiting.
- 11 Oct 2018 Planned initiation date changed from 1 Aug 2018 to 1 Oct 2018.
- 28 Aug 2018 New trial record